Efficacy of Topical Bevacizumab for Inhibiting Growth of Impending Recurrent Pterygium

Fallah, Mohammad Reza; Khosravi, Keivan; Hashemian, Morteza; Beheshtnezhad, A H; Rajabi, Mohammad Taher; Gohari, Mohsen

doi:10.3109/02713680903395273

Cited by 58 publications

(38 citation statements)

References 31 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bevaciuzmab has been used in the scenario of an impending recurrence of pterygium [8]. Intralesional bevacizumab, without surgery, has also been reported to reduce pterygium size [9].…”

Section: Discussionmentioning

confidence: 99%

“…It has been shown to be relatively safe, though untoward ocular and systemic side effects have been reported. Considering that primary pterygium, is a fibrovascular proliferation combined with subconjunctival elastotic degeneration [1] and that VEGF levels have been shown to be increased in pterygia and post inflammation [5], anti VEGFs have been used in treating primary and recurrent pterygia using different modes of administration [7][8][9][10][11][12][13]. Peak VEGF levels during the healing response have been found around day 7 post surgical or non surgical insult and subsequent inflammation, and this continues to day 30, when it gradually dies down [4,14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes of Post-Operative Topical Bevacizumab in Primary Pterygium Surgery: A Case Series

Sudhalkar¹,

Sudhalkar²

2012

J Clinic Experiment Ophthalmol

View full text Add to dashboard Cite

“…Bevaciuzmab has been used in the scenario of an impending recurrence of pterygium [8]. Intralesional bevacizumab, without surgery, has also been reported to reduce pterygium size [9].…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Outcomes of Post-Operative Topical Bevacizumab in Primary Pterygium Surgery: A Case Series

Sudhalkar¹,

Sudhalkar²

2012

J Clinic Experiment Ophthalmol

View full text Add to dashboard Cite

“…With the emergence and availability of antivascular endothelial growth factors (anti-VEGF), they were suggested as a possible adjunctive therapy for pterygium excision by decreasing the vascularity of newly formed blood vessels, hence decreasing the recurrence rate [12,13]. Intralesional injection of Bevacizumab was found by Fallah et al [14] to decrease pterygium size.…”

Section: Discussionmentioning

confidence: 99%

“…Many wound modulating agents have been used in a trial to minimize recurrence, including irradiation, antimetabolites namely; 5-fluorouracil and mitomycin C. They all carried some complications such as scleral thinning, corneal damage and consequences of radiation exposure. It has been well-established that pterygium is composed of fibrovascular tissue and the pterygium formation and progression require neovascularization, suggesting that the vascular endothelial growth factor (VEGF) is involved in the pathogenesis of pterygia [11].With the emergence and availability of antivascular endothelial growth factors (anti-VEGF), they were suggested as a possible adjunctive therapy for pterygium excision by decreasing the vascularity of newly formed blood vessels, hence decreasing the recurrence rate [12,13]. Intralesional injection of Bevacizumab was found by Fallah et al [14] to decrease pterygium size.…”

mentioning

confidence: 99%

Evaluation of the Additive Effect of Bevacizumab Eye Drops to Mitomycin C in Primary Pterygium

Fouda¹

2017

AOVS

View full text Add to dashboard Cite

Purpose: To assess the additive effect of postoperative Bevacizumab eye drops to MMC augmented bare sclera in cases of primary pterygium concerning the safety and recurrence rate. Patients and methods:This prospective randomized controlled study included 20 patients with bilateral primary pterygium. The right eye of each patient was treated by simple pterygium excision with bare sclera and MMC application followed by artificial tear eye drops for 4 weeks postoperative as placebo (group I included 20 eyes) and served as the control group. The left eye of each patient was treated by simple excision with bare sclera and MMC followed by topical Bevacizumab eye drops for 4 weeks postoperative (group II included 20 eyes). Both eyes were operated upon in the same session. All subjects were examined on days 1, 7,14 and 30 and monthly for year to record any vascularization measured in mm or recurrence of pterygium measured horizontally from the limbus to its apex in the cornea.Results: After 12 months of follow up, 3 eyes (15%) with recurrence were seen in group I which was not significantly different from group II with 2 eyes (10%). No corneal neovascularization in group II except in 7 eyes of which only 1-2 mm neovessels growth in 5 eyes and one eye more than 3mm and another eye 2-3 mm however in group I no vascularization in only 5 eyes with more than 3 mm neovessels in 3 eyes, 5 eyes with neovessels 2-3 mm and 7 eyes with 1-2 mm neovessels. Total P-Value concerning the presence and absence of vascularization between the two groups was 0.000805 which was highly significant. Conclusion:Our study concluded that recurrence was not affected by the topical Bevacizumab with no statistically significant difference between the two groups; however, a statistically significant difference existed in the level of corneal neovascularization between the two groups suggesting that regression of neovessels is not a guarantee against recurrence of pterygium. Keywords Patients and MethodsThis prospective randomized controlled study included 20 patients with bilateral primary pterygium. Written consent was obtained from the patients and included an explanation of the study and agreement to have a photo of the eye area only taken. This study work follows the recommendations of the Ethics Committee of Zagazig university (ZU-IRB) which conforms to the provisions of the Declaration of Helsinki in 1995 (as revised in Edinburgh 2000). The sample size was calculated to be 40 eyes, the calculation was done using Epi-Info (Epidemiological Information Package) software version 6.1. The patients were selected from the patients attending the outpatient clinic of ophthalmology department of Zagazig University Hospital during the period from November 2013 to December 2014.To ensure matching between the study groups, patients with bilateral pterygia only were included in the study and the right eye was randomly selected to be treated with MMC only while the left eye was randomly selected to be treated with both MMC and Bevacizumab. The right ...

show abstract

“…Delayed recurrence was observed in a study by Fallah et al, who used topical bevacizumab to inhibit the growth of impending recurrent pterygium in 26 eyes, although the pterygia eventually ex tended onto the cornea (17) . Other factors such as tumor necrosis factor alpha, bFGF, TGFβ, and plateletderived growth factor (PDGF) have been shown to correlate with the formation and recurrence of pterygium.…”

Section: A B C Dmentioning

confidence: 99%

Efficacy and safety of subconjunctival bevacizumab for recurrent pterygium

Stival¹,

Lago²,

Figueiredo³

et al. 2014

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Purpose: To evaluate the clinical outcome(s) and complication(s) of subcon junctival bevacizumab treatment in patients with recurrent pterygium. Methods: This prospective case series included patients who had undergone pterygium surgery and were diagnosed with recurrent pterygium. All patients received one subconjunctival injection of 0.5 mL of bevacizumab (2.5 mg/0.1 mL). The main outcome was the change in size and clinical appearance. The clinical appearance of the pterygium was graded according to Tan and colleagues. The horizontal size of the pterygium (from limbus to apex) was recorded from baseline to 2 months after injection. Treatmentrelated complications and adverse events were reported. Results: We included 36 eyes of 36 patients (18 males) with a mean age of 58.75 ± 10.98 years. Totally, 30.6% patients developed recurrent pterygium in both eyes (only the worst eye was treated), with 47.2% developing it in the left eye and 22.2% in the right eye. More than half the patients (58.3%) had a family history of pterygium. There was a significant difference in the size of pterygium at different intervals (P<0.05). Approximately twothirds (66.7%) of patients pre sented with hyposphagma on the 2 nd day after subconjunctival application; this value decreased to 30.6% by day 7 and to 0% at 1 month. Most patients (69.4%) ex hibited amelioration of irritative symptoms within 2 days, 88.9% after 7 days, and 97.2% after 1 month. Conclusions: Subconjunctival bevacizumab injection is useful for the manage ment of patients with recurrent pterygium, with no significant local or systemic adverse effects.

show abstract

Efficacy of Topical Bevacizumab for Inhibiting Growth of Impending Recurrent Pterygium

Abstract: Short-term use of topical bevacizumab seems to be a safe and effective means for delaying recurrence of impending recurrent pterygia.

Cited by 58 publications

References 31 publications

Outcomes of Post-Operative Topical Bevacizumab in Primary Pterygium Surgery: A Case Series

Outcomes of Post-Operative Topical Bevacizumab in Primary Pterygium Surgery: A Case Series

Evaluation of the Additive Effect of Bevacizumab Eye Drops to Mitomycin C in Primary Pterygium

Efficacy and safety of subconjunctival bevacizumab for recurrent pterygium

Contact Info

Product

Resources

About